General Information of DTT (ID: TTL1ATN)

DTT Name Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DTT Info
Gene Name CHRNA4-CHRNB2

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
2 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metocurine Iodide DMZJYBW Anaesthesia 9A78.6 Approved [1]
Varenicline DMMUOLJ Drug dependence Approved [2]
------------------------------------------------------------------------------------
6 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
AZD-1446 DM7B1AR Alzheimer disease 8A20 Phase 2 [3]
CP-601927 DMKJFDM Gastrointestinal disease DE2Z Phase 2 [4]
Sofinicline DM157U0 Attention deficit hyperactivity disorder 6A05.Z Phase 2 [5]
TC-6499-12 DMWPI2U Irritable bowel syndrome DD91.0 Phase 2 [6]
SUVN 911 DMZP671 Major depressive disorder 6A70.3 Phase 1 [7]
TC-2216 DM4W92J Mood disorder 6A60-6E23 Phase 1 [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Clinical Trial Drug(s)
5 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dianicline DMX2SHT Tobacco dependence 6C4A.2 Discontinued in Phase 3 [9]
ABT-089 DM8DT7U Anxiety disorder 6B00-6B0Z Discontinued in Phase 2 [10]
Ispronicline DMKY2UE Alzheimer disease 8A20 Discontinued in Phase 2 [11]
TC-2696 DMP1A4S Pain MG30-MG3Z Discontinued in Phase 2 [12]
SIB-1508Y DMT43AI Parkinson disease 8A00.0 Terminated [14]
------------------------------------------------------------------------------------
1 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
A-366833 DML5SO1 Pain MG30-MG3Z Preclinical [13]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 NMR study of general anesthetic interaction with nAChR beta2 subunit.Biophys J.2008 Mar 1;94(5):1681-8.
2 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
3 A randomized, double-blind, placebo-controlled crossover study of 4 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.Psychopharmacology (Berl). 2014 Mar;231(6):1251-65.
4 Toxicity study in juvenile rats with the alpha4beta2 nicotinic acetylcholine receptor partial agonist CP-601,927. Birth Defects Res B Dev Reprod Toxicol. 2011 Aug;92(4):323-32.
5 Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014 Aug;23(8):1157-63.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine alpha42 Receptor Antagonist for the Treatment of Depression. J Med Chem. 2020 Mar 26;63(6):2833-2853.
8 TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity.CNS Neurosci Ther.2008 Winter;14(4):266-77.
9 Dianicline, a novel 42 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial.Nicotine Tob Res.2011 Jan;13(1):1-6.
10 Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain.Biochem Pharmacol.2009 Oct 1;78(7):795-802.
11 Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. J Mol Neurosci. 2006;30(1-2):19-20.
12 alpha4beta2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology. 2013 Aug;71:191-203.
13 Antinociceptive activity of alpha4beta2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain. Eur J Pharmacol. 2011 Oct 1;668(1-2):155-62.
14 Nicotinic Receptors in Neurodegeneration